Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C

Aim – to evaluate the effect of direct antiviral drugs (sofosbuvir and velpatasvir) on the formation of the metabolic syndrome in patients with chronic hepatitis C with a high risk of its development 2 years after treatment.Materials and methods. 112 patients with HCV (n=112) were examined, in whom...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. F. Novikova, D. A. Kokorev, D. Yu. Konstantinov, L. L. Popova
Format:	Article
Language:	Russian
Published:	Journal Infectology 2023-07-01
Series:	Журнал инфектологии
Subjects:	chronic hepatitis c metabolic syndrome daa velpatasvir sofosbuvir antiviral therapy
Online Access:	https://journal.niidi.ru/jofin/article/view/1512
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective
by: Nambaru Vidya Sagar, et al.
Published: (2025-04-01)

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
by: Umut Devrim Binay, et al.
Published: (2025-06-01)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children
by: Salahuddin Mahmud, et al.
Published: (2025-06-01)

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan
by: Daisuke Nakamoto, et al.
Published: (2025-04-01)

Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study
by: Maria Pokorska-Śpiewak, et al.
Published: (2024-12-01)

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study
by: Jae Hyun Yoon, et al.
Published: (2025-07-01)

Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C
by: Tamer Fouad, et al.
Published: (2025-07-01)

Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad
by: Nagina Shahzadi, et al.
Published: (2023-04-01)

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
by: Ioana Adela Ratiu, et al.
Published: (2024-12-01)

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6
by: D. A. Lioznov, et al.
Published: (2017-04-01)

Antivirals against HCV infection: the story thus far
by: Ahmad Adebayo Irekeola, et al.
Published: (2022-02-01)

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region
by: Fahad Alghamdi, et al.
Published: (2024-06-01)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024-11-01)

HCV-related chronic kidney disease in the era of new direct-acting antivirals regimens
by: Jakub Janczura, et al.
Published: (2025-08-01)

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
by: Nawfal R Hussein
Published: (2017-01-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

The politics and governance of drug production in public-private partnerships: Brazil’s response to hepatitis C
by: Helena de Moraes Achcar, et al.
Published: (2024-12-01)

State and prospects of therapeutic treatment of children with chronic hepatitis C in the Russian Federation
by: A. A. Fomicheva, et al.
Published: (2021-03-01)

The impact of sofosbuvir/ledipasvir on chronic hepatitis C-infected paediatric patients: a Middle East single-centre experience
by: Mohammad Fadhil Ibraheem, et al.
Published: (2023-11-01)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)

Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population
by: Jowana Saba, et al.
Published: (2018-02-01)

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients
by: Sonia Younas, et al.
Published: (2021-10-01)

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
by: Tyng-Yuan Jang, et al.
Published: (2025-08-01)

Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study
by: Kaili Wang, et al.
Published: (2025-07-01)

Use of Hepatitis C Viremic Donors to Expand the Pediatric Donor Pool
by: Natasha Dilwali, et al.
Published: (2024-10-01)

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
by: Caesar Ferrari, et al.
Published: (2024-10-01)

Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir
by: L. L. Popova, et al.
Published: (2018-12-01)

Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China
by: Fan-Rong Jiang, et al.
Published: (2024-11-01)

A case report of sofosbuvir induced drug eruption and literature review
by: Anyue Xia, et al.
Published: (2025-01-01)

Application of dicarbamin in treatment of patients by a chronic hepatitis C
by: D. Yu. Konstantinov, et al.
Published: (2011-09-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

Impact of Sofosbuvir Plus Daclatasvir Therapy on the Frequency of CD200R<sup>+</sup> Dendritic Cells in Chronic Hepatitis C Virus Infection
by: Helal F. Hetta, et al.
Published: (2024-12-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Efficiency of Antiviral Therapy for Recurrence of Chronic Hepatitis C in Patients Undergoing Liver Transplantation
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

Time required to achieve optimum viral load suppression with Ravidasvir/sofosbuvir in chronic hepatitis C patients with or without compensated cirrhosis
by: Nor Asiah Muhamad, et al.
Published: (2025-04-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

POSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTS
by: V. E. Syutkin, et al.
Published: (2011-06-01)

Characteristics of lipid metabolism disorders in patients with coronavirus infection-COVID-19 with chronic hepatitis C
by: E. I. Temnik, et al.
Published: (2023-11-01)